Niagen Bioscience Inc., formerly ChromaDex, is a global bioscience company
uncovering
the potential of NAD+ with precision science. Led by world-renowned scientists working with global
research
institutions to pioneer research on nicotinamide adenine dinucleotide (NAD+), our company officially
changed its
name from ChromaDex to Niagen Bioscience, effective March 19, 2025, with our NASDAQ ticker symbol
changing from
"CDXC" to "NAGE."
NAD+ is an essential coenzyme, present in all living cells, and is fundamental to
mitochondrial bioenergetics, metabolic homeostasis, and genomic stability. Research shows NAD+ levels
decline
with age and metabolic stress, correlating with diminished cellular function and physiological
resilience.
Distinguished by uncompromising scientific standards over 25 years since its
inception, the company developed patented Niagen® (nicotinamide riboside, NR), which demonstrates
superior
efficacy compared to other NAD+ precursors in clinical trials. This proprietary compound powers
evidence-based
NAD+ enhancement solutions offered by our brands: pharmaceutical-grade intravenous (Niagen IV) and
injectable
formulations from Niagen® Plus, and high-bioavailability oral supplements from Tru Niagen®.
Our comprehensive intellectual property portfolio safeguards these innovations
while
we continue to advance the scientific understanding of NAD+ metabolism and its implications for human
health and
healthy aging.
Discover our industry leadership, Nobel Prize-winning research expertise, and
market-leading position in the rapidly expanding NAD+ sector.